Factors associated with neurocognitive test performance at baseline: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

HIV Medicine

Volumn 16, Issue S1, 2015, Pages 97-108

[No Author Info available]

Author keywords

Antiretroviral therapy na ve; HIV; HIV associated neurocognitive disorders; Neurocognitive performance

Indexed keywords

ADULT; ARGENTINA; ARTICLE; BODY MASS; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILE; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; HEMATOCRIT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; STANDARDIZATION; TASK PERFORMANCE; ADOLESCENT; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ARGENTINA; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILE; COGNITION DISORDERS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; YOUNG ADULT;

EID: 84923319955     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12238     Document Type: Article

References (36)

1. Bhaskaran K, Mussini C, Antinori A etal. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63: 213-221.
2. Satz P, Morgenstern H, Miller EN etal. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1993; 6: 503-511.
3. Wright EJ, Grund B, Robertson K etal. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010; 75: 864-873.
4. Childs EA, Lyles RH, Selnes OA etal. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999; 52: 607-613.
5. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006; 66: 1447-1450.
6. McArthur JC, Hoover DR, Bacellar H etal. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43: 2245-2252.
7. McCutchan JA, Marquie-Beck JA, Fitzsimons CA etal. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 2012; 78: 485-492.
8. Becker JT, Kingsley L, Mullen J etal. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology 2009; 73: 1292-1299.
9. Valcour VG, Shikuma CM, Shiramizu BT etal. Diabetes, insulin resistance, and dementia among HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 38: 31-36.
10. Sevigny JJ, Albert SM, McDermott MP etal. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004; 63: 2084-2090.
11. Stern Y, McDermott MP, Albert S etal. Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 2001; 58: 473-479.
12. Wachtman LM, Skolasky RL, Tarwater PM etal. Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol 2007; 64: 1264-1272.
13. Garvey LJ, Pavese N, Politis M etal. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS 2014; 28: 67-72.
14. Ragin AB, Du H, Ochs R etal. Structural brain alterations can be detected early in HIV infection. Neurology 2012; 79: 2328-2334.
15. Babiker AG, Emery S, Fatkenheuer G etal. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10: S5-S36.
16. Antinori A, Arendt G, Becker JT etal. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-1799.
17. Woods SP, Rippeth JD, Frol AB etal. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004; 26: 759-778.
18. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
19. Wright E, Brew B, Arayawichanont A etal. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology 2008; 71: 50-56.
20. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
21. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, Springer, 2001.
22. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2014.
23. Lezak MD, Howieson DB, Bigler ED, Tranel D, eds. Neuropsychological Assessment, Fifth edn. Oxford University Press, 2012.
24. Winston A, Arenas-Pinto A, Stohr W etal. Neurocognitive function in HIV infected patients on antiretroviral therapy. PLOS ONE 2013; 8: e61949.
25. Heaton RK, Clifford DB, Franklin DR, Jr etal. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087-2096.
26. Manly JJ, Smith C, Crystal HA etal. Relationship of ethnicity, age, education, and reading level to speed and executive function among HIV+ and HIV- women: the Women's Interagency HIV Study (WIHS) Neurocognitive Substudy. J Clin Exp Neuropsychol 2011; 33: 853-863.
27. Yeung SE, Fischer AL, Dixon RA. Exploring effects of type 2 diabetes on cognitive functioning in older adults. Neuropsychology 2009; 23: 1-9.
28. Ly TT, Anderson M, McNamara KA, Davis EA, Jones TW. Neurocognitive outcomes in young adults with early-onset type 1 diabetes: a prospective follow-up study. Diabetes Care 2011; 34: 2192-2197.
29. Gibellini D, Clo A, Morini S, Miserocchi A, Ponti C, Re MC. Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol 2013; 2: 91-101.
30. Ragin AB, Wu Y, Storey P, Cohen BA, Edelman RR, Epstein LG. Monocyte chemoattractant protein-1 correlates with subcortical brain injury in HIV infection. Neurology 2006; 66: 1255-1257.
31. Shikuma CM, Gangcuangco LM, Killebrew DA etal. The role of HIV and monocytes/macrophages in adipose tissue biology. J Acquir Immune Defic Syndr 2014; 65: 151-159.
32. Eguchi K, Manabe I. Toll-like receptor, lipotoxicity and chronic inflammation: the pathological link between obesity and cardiometabolic disease. J Atheroscler Thromb 2014; 21: 629-639.
33. Peluso MJ, Meyerhoff DJ, Price RW etal. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis 2013; 207: 1703-1712.
34. Weber E, Morgan EE, Iudicello JE etal. Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol 2013; 19: 65-74.
35. Cysique LA, Deutsch R, Atkinson JH etal. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc 2007; 13: 1-11.
36. INSIGHT START Study Group. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med 2015; 16 (Suppl 1): 1-9.